Your browser doesn't support javascript.
loading
Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics.
Kim, Tae-Rim; Won, Yumi; Kim, Yeona; Won, Sang-Hyeon; Bae, Kyung-Nam; Lee, Jungsoo; Shin, Kihyuk; Kim, Hoonsoo; Ko, Hyunchang; Kim, Moon-Bum; Kim, Byungsoo.
Afiliação
  • Kim TR; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • Won Y; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • Kim Y; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Won SH; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Bae KN; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Lee J; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Shin K; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Kim H; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Ko H; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Kim MB; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.
  • Kim B; Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Eur J Dermatol ; 33(5): 518-523, 2023 Oct 01.
Article em En | MEDLINE | ID: mdl-38297928
ABSTRACT
The Psoriasis Area and Severity Index (PASI) 100 response rate after treatment with biologics is reportedly lower in Asians than non-Asians. Large-scale studies evaluating predictors of PASI 100 response in Korean patients with psoriasis are yet to be conducted. To identify predictors of patients achieving PASI 100 response after 48-52 weeks of treatment with a biological agent. We retrospectively reviewed the medical records of 145 patients with psoriasis treated with a single biological agent for over one year. Clinical features were compared between super-responders (defined as achieving PASI 100 at 48-52 weeks) and non-super-responders. Among the patients included in the study, 61 (42.1%) were super-responders. No statistical difference in demographics and face, scalp, or nail involvement was observed. However, the mean body mass index (BMI) and baseline PASI were lower in super-responders (24.3 kg/m2, 14.3) than in non-super-responders (26.1 kg/m2, 16.2). There were more biologically naïve patients among the super-responders (85.2%) than the non-super-responders (67.9%). In Korean patients with moderate-to-severe psoriasis, a better PASI 100 response is expected for patients who are biologically naïve with a relatively lower baseline BMI and PASI.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Produtos Biológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Produtos Biológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article